122 related articles for article (PubMed ID: 37224228)
1. Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma.
Look T; Puca E; Bühler M; Kirschenbaum D; De Luca R; Stucchi R; Ravazza D; Di Nitto C; Roth P; Katzenelenbogen Y; Weiner A; Rindlisbacher L; Becher B; Amit I; Weller M; Neri D; Hemmerle T; Weiss T
Sci Transl Med; 2023 May; 15(697):eadf2281. PubMed ID: 37224228
[TBL] [Abstract][Full Text] [Related]
2. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Walbert T; Gilbert MR; Groves MD; Puduvalli VK; Yung WK; Conrad CA; Bobustuc GC; Colman H; Hsu SH; Bekele BN; Qiao W; Levin VA
J Neurooncol; 2011 Apr; 102(2):273-80. PubMed ID: 20652724
[TBL] [Abstract][Full Text] [Related]
3. Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
Yamamuro S; Takahashi M; Satomi K; Sasaki N; Kobayashi T; Uchida E; Kawauchi D; Nakano T; Fujii T; Narita Y; Kondo A; Wada K; Yoshino A; Ichimura K; Tomiyama A
Cancer Sci; 2021 Nov; 112(11):4736-4747. PubMed ID: 34536314
[TBL] [Abstract][Full Text] [Related]
4. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
Fishman H; Monin R; Dor-On E; Kinzel A; Haber A; Giladi M; Weinberg U; Palti Y
J Neurooncol; 2023 May; 163(1):83-94. PubMed ID: 37131108
[TBL] [Abstract][Full Text] [Related]
5. Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.
Kim SH; Yoo H; Chang JH; Kim CY; Chung DS; Kim SH; Park SH; Lee YS; Yang SH
J Korean Med Sci; 2018 Jun; 33(24):e167. PubMed ID: 29892208
[TBL] [Abstract][Full Text] [Related]
6. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
7. Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Yagiz K; Huang TT; Lopez Espinoza F; Mendoza D; Ibañez CE; Gruber HE; Jolly DJ; Robbins JM
Neuro Oncol; 2016 Oct; 18(10):1390-401. PubMed ID: 27166379
[TBL] [Abstract][Full Text] [Related]
8. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
Stritzelberger J; Distel L; Buslei R; Fietkau R; Putz F
Clin Transl Oncol; 2018 Apr; 20(4):508-516. PubMed ID: 28825189
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.
Staberg M; Michaelsen SR; Rasmussen RD; Villingshøj M; Poulsen HS; Hamerlik P
Cell Oncol (Dordr); 2017 Feb; 40(1):21-32. PubMed ID: 27766591
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
[TBL] [Abstract][Full Text] [Related]
12. Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
Erdem-Eraslan L; van den Bent MJ; Hoogstrate Y; Naz-Khan H; Stubbs A; van der Spek P; Böttcher R; Gao Y; de Wit M; Taal W; Oosterkamp HM; Walenkamp A; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; van der Holt B; Vernhout RM; Sillevis Smitt PA; Kros JM; French PJ
Cancer Res; 2016 Feb; 76(3):525-34. PubMed ID: 26762204
[TBL] [Abstract][Full Text] [Related]
13. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
Puigdelloses M; Garcia-Moure M; Labiano S; Laspidea V; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; De la Nava D; Ausejo I; Hervás-Stubbs S; Herrador G; Chen Z; Hambardzumyan D; Patino Garcia A; Jiang H; Gomez-Manzano C; Fueyo J; Gállego Pérez-Larraya J; Alonso M
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281988
[TBL] [Abstract][Full Text] [Related]
14. Misonidazole and CCNU chemotherapy for recurrent primary brain tumor.
Fulton DS; Urtasun RC; McKinnon S; Tanasichuk H
J Neurooncol; 1987; 4(4):383-8. PubMed ID: 3033164
[TBL] [Abstract][Full Text] [Related]
15. Targeting Homologous Recombination by Pharmacological Inhibitors Enhances the Killing Response of Glioblastoma Cells Treated with Alkylating Drugs.
Berte N; Piée-Staffa A; Piecha N; Wang M; Borgmann K; Kaina B; Nikolova T
Mol Cancer Ther; 2016 Nov; 15(11):2665-2678. PubMed ID: 27474153
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis.
Song J; Xue YQ; Zhao MM; Xu P
Onco Targets Ther; 2018; 11():3435-3439. PubMed ID: 29942135
[TBL] [Abstract][Full Text] [Related]
17. Lung toxicity of lomustine in the treatment of progressive gliomas.
Seliger C; Nürnberg C; Wick W; Wick A
Neurooncol Adv; 2022; 4(1):vdac068. PubMed ID: 35664555
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
Weathers SP; Han X; Liu DD; Conrad CA; Gilbert MR; Loghin ME; O'Brien BJ; Penas-Prado M; Puduvalli VK; Tremont-Lukats I; Colen RR; Yung WKA; de Groot JF
J Neurooncol; 2016 Sep; 129(3):487-494. PubMed ID: 27406589
[TBL] [Abstract][Full Text] [Related]
19. EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.
Franceschi E; Stupp R; van den Bent MJ; van Herpen C; Laigle Donadey F; Gorlia T; Hegi M; Lhermitte B; Strauss LC; Allgeier A; Lacombe D; Brandes AA
Neuro Oncol; 2012 Dec; 14(12):1503-10. PubMed ID: 23090987
[TBL] [Abstract][Full Text] [Related]
20. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H
Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
